Zobrazeno 1 - 10 of 115 pro vyhledávání: '"S L, Choi"'
1
Akademický článek
COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition
Autor: Shilin Zhao, Kris Y. W. Lok, Zhen Y. Sin, Ye Peng, Heidi S. L. Fan, Nitya Nagesh, Martha S. L. Choi, Jojo Y. Y. Kwok, Edmond P. H. Choi, Xi Zhang, Hogan Kok-Fung Wai, Leo C. H. Tsang, Samuel S. M. Cheng, Matthew K. L. Wong, Jie Zhu, Chris K. P. Mok, Siew C. Ng, Francis K. L. Chan, Malik Peiris, Leo L. M. Poon, Hein M. Tun
Publikováno v: npj Vaccines, Vol 8, Iss 1, Pp 1-11 (2023)
Abstract Newborns can acquire immunological protection to SARS-CoV-2 through vaccine-conferred antibodies in human breast milk. However, there are some concerns around lactating mothers with regards to potential short- and long-term adverse events an
Externí odkaz: https://doaj.org/article/97c98fea7c374c10952279eef846a51e
Zobrazit plný text záznamu
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Pharmacokinetics of the Long‐Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function
Autor: Teri S. Hodgson, S. L. Choi, Helle Linnebjerg, Vikram Sinha, Kenneth F. Mace, Eric Chen Quin Lam
Publikováno v: Clinical Pharmacology in Drug Development
The pharmacokinetics of LY2605541 (basal insulin peglispro), a novel long‐acting basal insulin analogue, was evaluated in 5 groups of subjects with varying degrees of renal function based on creatinine clearance: normal renal function (>80 mL/min),
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8eff106923c8c5363682e019d5a6f71d
https://doi.org/10.1002/cpdd.252
Zobrazit plný text záznamu
4
Surface roughness estimation and visualisation using force feedback
Autor: H. B. Hong, C. B. Kim, S. L. Choi, J. W. Park, Jae-guyn Lim, E. G. Lim
Publikováno v: Electronics Letters. 53:1651-1653
The authors suggest a simple visualisation system for the surface roughness information, with being highly cost-effective, non-destructive for the surface, curved-surface measurable, and standard-compensated. This system utilises a force sensor with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f9774dfe238e4173a93aa0372673e269
https://doi.org/10.1049/el.2016.4408
Zobrazit plný text záznamu
7
Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects
Autor: Theodore P. Ciaraldi, Eric Chen Quin Lam, Debra Armstrong, Helle Linnebjerg, Melvin J. Prince, Scott J. Jacober, Parag Garhyan, Niels Porksen, Robert R. Henry, Paivi Burke, Jeremy Pettus, Vikram Sinha, Namrata Bose, S. L. Choi, Sunder Mudaliar, Mary Pat Knadler
Publikováno v: Diabetes Care. 37:2609-2615
OBJECTIVE We evaluated the endogenous glucose production (EGP) and glucose disposal rate (GDR) over a range of doses of basal insulin peglispro (BIL) and insulin glargine in healthy subjects. RESEARCH DESIGN AND METHODS This was a single-center, rand
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2238febef329b249223438b3bd990d08
https://doi.org/10.2337/dc14-0210
Zobrazit plný text záznamu
8
Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects
Autor: Danny Soon, Shufen T. H. Lim, Vikram Sinha, Kenneth F. Mace, S. L. Choi, Kwee Poo Yeo, Daniel C. Howey
Publikováno v: The Journal of Clinical Pharmacology. 54:792-799
LY2605541 is a novel basal insulin analog with a prolonged duration of action. Two Phase I studies assessed LY2605541 pharmacokinetics (PK), glucodynamics (GD), and tolerability in healthy subjects. In Study 1, 33 subjects received single subcutaneou
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::75e4c0639375f756cee4d31752fe77a4
https://doi.org/10.1002/jcph.276
Zobrazit plný text záznamu
9
Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus
Autor: Kenneth F. Mace, Vikram Sinha, Daniel C. Howey, T. Heise, S. L. Choi
Publikováno v: Diabetes, Obesity and Metabolism. 16:344-350
Aims To assess the pharmacokinetics (PK) and glucodynamics (GD) of LY2605541 in patients with type 2 diabetes mellitus. Methods This parallel-group, open-label, dose-escalation study examined the PK and GD of basal insulin LY2605541 after single and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::74760453992e1db97ae26f7f3044fb25
https://doi.org/10.1111/dom.12222
Zobrazit plný text záznamu
10
Reduced peripheral activity leading to hepato-preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes
Autor: Parag Garhyan, Niels Porksen, Paivi Burke, S. L. Choi, Mary Pat Knadler, Robert R. Henry, Helle Linnebjerg, Vikram Sinha, Debra Armstrong, Eric Chen Quin Lam, Theodore P. Ciaraldi, Scott J. Jacober, Jeremy Pettus, Sunder Mudaliar, N. Bose, Melvin J. Prince
Publikováno v: Diabetes, obesitymetabolism. 18
Aims Basal insulin peglispro (BIL), a novel PEGylated basal insulin with a large hydrodynamic size, has a delayed absorption and reduced clearance that prolongs the duration of action. The current study compared the effects of BIL and insulin glargin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9ace8bb4de6345d07a9c2895e1f920f
https://pubmed.ncbi.nlm.nih.gov/27723226
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje